Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, January 17, 2023
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
[ Tue, Jan 17th 2023
] - WOPRAI
Yasmeen Rahimi Maintained (ALGS) at Buy with Increased Target to $175 on, Jan 17th, 2023
Yasmeen Rahimi of Piper Sandler, Maintained "Aligos Therapeutics, Inc." (ALGS) at Buy with Increased Target from $75 to $175 on, Jan 17th, 2023.
Yasmeen has made no other calls on ALGS in the last 4 months.
There are 2 other peers that have a rating on ALGS. Out of the 2 peers that are also analyzing ALGS, 1 agrees with Yasmeen's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Roanna Ruiz of "SVB Leerink" Maintained at Hold with Decreased Target to $50 on, Thursday, November 3rd, 2022
This is the rating of the analyst that currently disagrees with Yasmeen
- Michael Yee of "Jefferies" Upgraded from Hold to Strong Buy and Increased Target to $75 on, Friday, January 6th, 2023
